Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 1351 to 1360 of 1864 total matches.

In Brief: Two Intranasal Corticosteroid HFA Aerosols for Allergic Rhinitis (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 15, 2012  (Issue 1401)
for 30 days’ treatment. Source: PricePointRx™ October 5, 2012. Reprinted with permission by FDB, Inc ...
The FDA has approved 2 intranasal HFA (hydrofluoroalkane) aerosols of the corticosteroids beclomethasone dipropionate (Qnasl – Teva Respiratory) and ciclesonide (Zetonna – Sunovion) for once-daily treatment of seasonal and perennial allergic rhinitis. They are the first HFA nasal steroids to become available in the US (HFA propellants do not deplete the ozone layer). Both drugs are already available for these indications as aqueous nasal sprays. Aqueous ("wet") formulations can cause adverse effects such as postnasal drip, moist feeling in the nose, strong odor, and bitter aftertaste,...
Med Lett Drugs Ther. 2012 Oct 15;54(1401):84 |  Show IntroductionHide Introduction

In Brief: Plan B One-Step OTC

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2013  (Issue 1419)
within 1 hour of administration can repeat the dose. A copper IUD inserted within 5 days after ...
The progestin levonorgestrel is available over the counter for emergency contraception as two 0.75-mg tablets taken 12 hours apart (generic formulations of Plan B) and as a single 1.5-mg tablet taken once (Plan B One-Step, and generics). A third emergency contraceptive, ulipristal (Ella – Watson), is available with a prescription.1 It appears that, pursuant to a court order, Plan B One-Step (but not the generic products), which was previously available over the counter from a pharmacist only for women 17 years and older, will now be available directly from pharmacy shelves with no age...
Med Lett Drugs Ther. 2013 Jun 24;55(1419):52 |  Show IntroductionHide Introduction

In Brief: Prevention of Meningococcal B Disease

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 2013  (Issue 1431)
rifampin 600 mg (10 mg/kg for children) q12h for 2 days; oral ciprofloxacin 500 mg once (not recommended ...
An outbreak (8 cases to date) of meningococcal disease at Princeton University caused by Neisseria meningitidis serogroup B has led the FDA and CDC to permit importation and investigational use (at Princeton University only) of a meningococcus B vaccine (4CMenB; Bexsero – Novartis) that has not been approved in the US. Bexsero has been approved for use in the European Union and in Australia.THE VACCINE — Until recently, no serogroup B vaccine was widely available because the polysaccharide capsule of the B serogroup, unlike those of the other main meningococcal serogroups (A, C, Y, and...
Med Lett Drugs Ther. 2013 Dec 9;55(1431):97 |  Show IntroductionHide Introduction

In Brief: Duopa - A Carbidopa/Levodopa Enteral Suspension for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Aug 03, 2015  (Issue 1474)
mg (1 cassette/day). Patients must also take oral immediate-release carbidopa/levodopa ...
The FDA has approved Duopa (Abbvie), a carbidopa/levodopa enteral suspension, for treatment of motor fluctuations in patients with advanced Parkinson's disease (PD). It has been available in Europe since 2001.In patients with advanced PD, emptying of the stomach may be delayed and unpredictable, which can affect the rate and amount of absorption of carbidopa/levodopa and its efficacy. To bypass the stomach, the new formulation is delivered through a nasojejunal (NJ) tube or percutaneous endoscopic gastrostomy with jejunal (PEG-J) tube.A randomized, double-blind, active-controlled, 12-week...
Med Lett Drugs Ther. 2015 Aug 3;57(1474):112 |  Show IntroductionHide Introduction

In Brief: Hypertension with Erenumab (Aimovig)

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021  (Issue 1621)
. Of the 44 cases in which time to onset was reported, 28 occurred ≤7 days after the most recent dose ...
The once-monthly, subcutaneously injected calcitonin gene-related peptide (CGRP) receptor antagonist erenumab-aooe (Aimovig) was approved by the FDA in 2018 for preventive treatment of migraine in adults. Now the FDA has added a new warning to its labeling about a risk of new-onset hypertension and worsening of preexisting hypertension associated with use of the drug. CGRP is a potent microvascular vasodilator; blocking or deleting it has produced hypertensive effects in animals.
Med Lett Drugs Ther. 2021 Apr 5;63(1621):56 |  Show IntroductionHide Introduction

Ruxolitinib (Opzelura) for Atopic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022  (Issue 1642)
and itching associated with AD within a few days and are often used as maintenance treatment to minimize use ...
The FDA has approved a 1.5% topical cream formulation of the Janus kinase (JAK) inhibitor ruxolitinib (Opzelura – Incyte) for short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients ≥12 years old whose disease has not been adequately controlled with other topical prescription drugs. Ruxolitinib is the first JAK inhibitor to be approved for topical use and the first to be approved in the US for treatment of AD. An oral formulation of ruxolitinib (Jakafi) is approved for treatment of myelofibrosis, polycythemia...
Med Lett Drugs Ther. 2022 Jan 24;64(1642):12-3 |  Show IntroductionHide Introduction

Sunscreens

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025  (Issue 1731)
every 2 hours [4 times per day] to 75% of body surface area) for 4 days; the 4 active ingredients ...
Excessive exposure to ultraviolet (UV) radiation can cause erythema, photoaging, and skin cancer. Sunscreens are widely used to reduce these risks, but questions remain about their effectiveness and safety. In 2021, the FDA proposed a rule that would require additional safety studies for some sunscreen active ingredients and mandate better UVA protection in sunscreen products.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):97-102   doi:10.58347/tml.2025.1731a |  Show IntroductionHide Introduction

Cisapride for Nocturnal Heartburn

   
The Medical Letter on Drugs and Therapeutics • Feb 04, 1994  (Issue 915)
FOR REFLUX ESOPHAGITIS — A randomized controlled trial in 177 patients with heartburn day and night ...
Cisapride (Propulsid - Janssen), a piperidinyl benzamide prokinetic drug, is now available in the USA for symptomatic relief of nocturnal heartburn due to gastroesophageal reflux disease. In Canada, cisapride is also marketed for treatment of gastroparesis.
Med Lett Drugs Ther. 1994 Feb 4;36(915):11-3 |  Show IntroductionHide Introduction

Fluoxetine (Prozac) and Other Drugs for Treatment of Obesity

   
The Medical Letter on Drugs and Therapeutics • Nov 25, 1994  (Issue 936)
supply of Ionamin at 15 mg per day and Pondimin at 60 mg per day would be about $55, according ...
Recent reports have suggested that some obese patients may benefit from long-term pharmacologic treatment (RL Atkinson and VS Hubbard, Am J Clin Nutr, 60:153, August 1994; DJ Goldstein and JH Potvin, Am J Clin Nutr, 60:647, November 1994). Fluoxetine (Prozac), widely used for treatment of depression and near approval by the US Food and Drug Administration (FDA) for treatment of bulimia, is also being tried for treatment of obesity.
Med Lett Drugs Ther. 1994 Nov 25;36(936):107-8 |  Show IntroductionHide Introduction

Botulinum Toxin (Botox Cosmetic) for Frown Lines

   
The Medical Letter on Drugs and Therapeutics • May 27, 2002  (Issue 1131)
, and 132 patients received placebo injections. Most (82%) of the patients were women. Thirty days after ...
Botulinum toxin type A (Botox Cosmetic - Allergan) has received formal approval from the FDA for treatment of glabellar ("frown") lines in adults not more than 65 years old, and is being heavily advertised. Even before this approval, cosmetic use of botulinum toxin to reduce wrinkles on the face and neck had become a popular alternative to cosmetic surgery (Medical Letter 1999; 41:63). Botulinum toxin type A (Botox) and type B (Myobloc) are approved for treatment of cervical dystonia (Medical Letter 2001; 43:53), and type A has been approved since 1989 for treatment of strabismus and...
Med Lett Drugs Ther. 2002 May 27;44(1131):47-8 |  Show IntroductionHide Introduction